A Phase 3 interventional study of PP6M injection Dose 1 and PP6M injection Dose 2 in Schizophrenia, sponsored by Janssen Research & Development, LLC. Completed at 30 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 58th largest by enrollment, is one of 2 that started in 2019, is one of 41 in phase 3, and was the 104th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 178 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 87th largest by enrollment of the 176 interventional ones that give a count, is the only one that started in 2019, is one of 74 in phase 3, and was the 199th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess the long-term safety and tolerability of paliperidone 6-month PP6M (Dose 1 or Dose 2 [milligram] mg eq.) and to provide access to PP6M in participants with schizophrenia completing the R092670PSY3015 study without relapse.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who enter the this open-label extension study immediately after completing Double-blind Phase Study R092670PSY3015 (previous study) will receive Paliperidone Palmitate 6 month (PP6M) intramuscular (IM) injections, dose will be selected based on the unblinded dose level ("moderate" or "higher") that the participant received during previous study. Participants in the "moderate" dose level will receive PP6M Dose 1 and "higher" dose level will receive PP6M Dose 2 during the open-label extension. The PP6M dose level may be adjusted (to Dose 1 or Dose 2) for every 6 month at Visits 3, 5, and 7, based on clinical judgment. Participants who enter this open-label extension study later (up to 3 months after they complete previous study) and were on a moderate or higher dose of PP3M (350 or 525 mg eq.) or PP1M (100 or 150 mg eq.) will receive initial dose of PP6M IM injection (Dose 1 or Dose 2) for every 6 months.
Drug: PP6M injection Dose 1 · Drug: PP6M injection Dose 2
Participants will receive Dose 1 PP6M intramuscular (IM) injection at Visit 1 (Day) then once every 6 month up to 24 months.
Also known as: R092670
Participants will receive Dose 2 PP6M IM injection at Visit 1 (Day) then once every 6 month up to 24 months.
Also known as: R092670
Number of Participants With Relapse
Number of participants with relapse were reported. Relapse is defined as one or more of the following: a) Psychiatric hospitalization for schizophrenia (involuntary or voluntary admission to a psychiatric hospital for decompensation of the participant's schizophrenic symptoms); b) Emergency Department/Room/Ward visit due to a worsening of the participant's symptoms of schizophrenia, but a psychiatric hospitalization does not occur; c) The participant inflicts deliberate self-injury or exhibits violent behaviour resulting in suicide, clinically significant injury to him/herself or another person, or significant property damage; d) The participant has suicidal or homicidal ideation and aggressive behaviour that is clinically significant (in frequency and severity) in the investigator's judgment.
Time frame: Up to Day 730
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs are those events if they started after administration of the first dose and until 183 days after the last dose of study medication.
Time frame: Up to Day 730
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale Score
Change from baseline in CGI-S scale score was reported. CGI-S is defined as clinician-rated scale that assesses the severity of mental illness on a scale of 0 to 7. Considering total clinical experience, a participant was assessed on severity of mental illness at the time of rating according to:1: normal, not at all ill; 2: borderline mentally ill; 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill participants. A higher score implies a more severe condition.
Time frame: Baseline up to Day 730
Change From Baseline in Personal and Social Performance (PSP) Scale Score
Change from baseline in PSP scale score was reported. The PSP scale assesses degree of a participant's dysfunction within 4 domains of behavior: 1) socially useful activities, 2) personal and social relationships, 3) self-care, and 4) disturbing and aggressive behavior. Each domain was assessed on a 6-point scale, from 1 (absent) to 6 (very severe) (1 = absent, 2 = mild, 3 = manifest, 4 = marked, 5 = severe, and 6 = very severe). PSP total score was calculated as sum of all the domain scores and ranges from 1 to 100. Participants with score of 71 to 100 had mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision. Higher score indicates better performance.
Time frame: Baseline up to Day 730
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score
Change from baseline in PANSS total score were reported. The neuropsychiatric symptoms of schizophrenia were assessed using the 30-item PANSS scale, which provides a total score (sum of the scores for all 30 items) and scores for 3 subscales: the 7-item positive-symptom (P) subscale, the 7-item negative-symptom (N) subscale, and the 16-item general-psychopathology symptom (G) subscale. Each item is rated on a scale of 1 (absent) to 7 (extreme). The PANSS total score ranges from 30 (absent disease)-210 (more severe neuropsychiatric symptoms of schizophrenia).
Time frame: Baseline up to Day 730
| Milestone | Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. |
|---|---|
| Started | 178 |
| Completed | 154 |
| Not completed | 24 |
| Withdrew: Physician decision | 1 |
| Withdrew: Adverse event | 7 |
| Withdrew: Withdrawal by subject | 14 |
| Withdrew: Other | 2 |
Number of participants with relapse were reported. Relapse is defined as one or more of the following: a) Psychiatric hospitalization for schizophrenia (involuntary or voluntary admission to a psychiatric hospital for decompensation of the participant's schizophrenic symptoms); b) Emergency Department/Room/Ward visit due to a worsening of the participant's symptoms of schizophrenia, but a psychiatric hospitalization does not occur; c) The participant inflicts deliberate self-injury or exhibits violent behaviour resulting in suicide, clinically significant injury to him/herself or another person, or significant property damage; d) The participant has suicidal or homicidal ideation and aggressive behaviour that is clinically significant (in frequency and severity) in the investigator's judgment.
| Participants | Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. |
|---|---|
| Number of Participants With Relapse | 7 |
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs are those events if they started after administration of the first dose and until 183 days after the last dose of study medication.
| Participants | Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 111 |
Change from baseline in CGI-S scale score was reported. CGI-S is defined as clinician-rated scale that assesses the severity of mental illness on a scale of 0 to 7. Considering total clinical experience, a participant was assessed on severity of mental illness at the time of rating according to:1: normal, not at all ill; 2: borderline mentally ill; 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill participants. A higher score implies a more severe condition.
| Units on a scale | Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. |
|---|---|
| Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale Score | 0.0 ± 0.51 |
Change from baseline in PSP scale score was reported. The PSP scale assesses degree of a participant's dysfunction within 4 domains of behavior: 1) socially useful activities, 2) personal and social relationships, 3) self-care, and 4) disturbing and aggressive behavior. Each domain was assessed on a 6-point scale, from 1 (absent) to 6 (very severe) (1 = absent, 2 = mild, 3 = manifest, 4 = marked, 5 = severe, and 6 = very severe). PSP total score was calculated as sum of all the domain scores and ranges from 1 to 100. Participants with score of 71 to 100 had mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision. Higher score indicates better performance.
| Units on a scale | Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. |
|---|---|
| Change From Baseline in Personal and Social Performance (PSP) Scale Score | 0.5 ± 7.47 |
Change from baseline in PANSS total score were reported. The neuropsychiatric symptoms of schizophrenia were assessed using the 30-item PANSS scale, which provides a total score (sum of the scores for all 30 items) and scores for 3 subscales: the 7-item positive-symptom (P) subscale, the 7-item negative-symptom (N) subscale, and the 16-item general-psychopathology symptom (G) subscale. Each item is rated on a scale of 1 (absent) to 7 (extreme). The PANSS total score ranges from 30 (absent disease)-210 (more severe neuropsychiatric symptoms of schizophrenia).
| Units on scale | Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. |
|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score | 0.7 ± 8.22 |
Collected over Up to Day 730. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. | 0/178 (0%) | 8/178 (4.5%) | 68/178 (38.2%) |
| Event | Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. |
|---|---|
| SchizophreniaPsychiatric disorders | 4/178 |
| Colon CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/178 |
| Metastases to PeritoneumNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/178 |
| Hallucination, AuditoryPsychiatric disorders | 1/178 |
| Psychiatric SymptomPsychiatric disorders | 1/178 |
| Nephrotic SyndromeRenal and urinary disorders | 1/178 |
| Event | Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. |
|---|---|
| HeadacheNervous system disorders | 24/178 |
| Blood Prolactin IncreasedInvestigations | 19/178 |
| HyperprolactinaemiaEndocrine disorders | 13/178 |
| DiarrhoeaGastrointestinal disorders | 11/178 |
| NasopharyngitisInfections and infestations | 9/178 |
| Weight IncreasedInvestigations | 9/178 |
| Age, Continuous(years) | Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. |
|---|---|
| Mean | 40.4 ± 10.76 |
| Sex: Female, Male(Participants) | Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. |
|---|---|
| Female | 52 |
| Male | 126 |
| Ethnicity (NIH/OMB)(Participants) | Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. |
|---|---|
| Hispanic or Latino | 48 |
| Not Hispanic or Latino | 130 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 176 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Sep 2019 to primary completion in May 2022, 31 months.
Results were first posted in May 2023, 1 year after primary completion.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 31 months is close to that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone
Janssen Research & Development, LLC →